文献速递功能神经外科神经肿瘤

颞叶癫痫手术历史队列:系统综述与meta分析指导未来非随机对照试验

A historical cohort of temporal lobe surgery for medically refractory epilepsy: a systematic review and meta-analysis to guide future nonrandomized controlled trial studies.
PubMed 文献 · J Neurosurg · 2019-06-28

该研究对成人颞叶癫痫的3项随机对照试验(RCT)进行系统综述与meta分析,报告总体Engel I级无发作率为72.4%(55/76例),与前瞻性队列的71.7%(1325/1849例)几乎一致,手术优于药物治疗(RR 10.82,95%CI 3.93-29.84,P<0.01),历史基准可提高非劣效设计检验效能。

要点

  • 成人颞叶癫痫手术总体无发作率约70%,I级与II级证据高度一致。
  • 手术较药物治疗显著改善无发作结局(RR 10.82,95%CI 3.93-29.84)。
  • 历史基准用于非劣效设计较单队列显著提高检验效能(P<0.001)。

核心结论

  • 药物难治性颞叶癫痫手术总体无发作率约70%。
  • RCT样本量小,提示需超越标准RCT研究手术结局。
  • 历史无发作率可作为未来新手术研究设计的基准。

研究设计与样本

  • 系统综述与meta分析,纳入3项成人颞叶癫痫RCT的I级数据。
  • 另收集18项前瞻性队列研究(II级数据)用于验证。
  • 排除回顾性研究,采用固定效应模型合并数据。

主要发现

  • I级数据总体无发作率72.4%(55/76例,3项RCT)。
  • II级数据总体无发作率71.7%(1325/1849例,18项研究),与I级比较z=0.134,P=0.89。
  • I级与II级无发作率随发表年份一致(R2<0.01,P=0.73)。
  • 手术较药物治疗无发作结局RR 10.82(95%CI 3.93-29.84,P<0.01;2项RCT)。
  • 历史基准非劣效设计较单队列在所有差异界值下检验效能更高(P<0.001)。

关键数值与推荐

  • 主要结局为术后总体无发作(Engel I级)。
  • I级数据无发作率72.4%(55/76例),II级数据71.7%(1325/1849例)。
  • 手术vs药物RR 10.82(95%CI 3.93-29.84,P<0.01)。

临床怎么用

  • 颞叶癫痫手术无发作率约70%可作为咨询与质量评估参考。
  • 新手术干预研究可考虑历史基准非劣效设计替代标准RCT。

局限性

  • RCT样本量小(3项研究共76例),限制标准RCT可行性。
  • 仅纳入RCT和前瞻性队列,排除回顾性研究以减少异质性和报告偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Recent trials for temporal lobe epilepsy (TLE) highlight the challenges of investigating surgical outcomes using randomized controlled trials (RCTs). Although several reviews have examined seizure-freedom outcomes from existing data, there is a need for an overall seizure-freedom rate estimated from level I data as investigators consider other methods besides RCTs to study outcomes related to new surgical interventions. METHODS: The authors performed a systematic review and meta-analysis of the 3 RCTs of TLE in adults and report an overall surgical seizure-freedom rate (Engel class I) composed of level I data. An overall seizure-freedom rate was also collected from level II data (prospective cohort studies) for validation. Eligible studies were identified by filtering a published Cochrane meta-analysis of epilepsy surgery for RCTs and prospective studies, and supplemented by searching indexed terms in MEDLINE (January 1, 2012-April 1, 2018). Retrospective studies were excluded to minimize heterogeneity in patient selection and reporting bias. Data extraction was independently reverified and pooled using a fixed-effects model. The primary outcome was overall seizure freedom following surgery. The historical benchmark was applied in a noninferiority study design to compare its power to a single-study cohort. RESULTS: The overall rate of seizure freedom from level I data was 72.4% (55/76 patients, 3 RCTs), which was nearly identical to the overall seizure-freedom rate of 71.7% (1325/1849 patients, 18 studies) from prospective cohorts (z = 0.134, p = 0.89; z-test). Seizure-freedom rates from level I and II studies were consistent over the years of publication (R2 < 0.01, p = 0.73). Surgery resulted in markedly improved seizure-free outcomes compared to medical management (RR 10.82, 95% CI 3.93-29.84, p < 0.01; 2 RCTs). Noninferiority study designs in which the historical benchmark was used had significantly higher power at all difference margins compared to using a single cohort alone (p < 0.001, Bonferroni's multiple comparison test). CONCLUSIONS: The overall rate of seizure freedom for temporal lobe surgery is approximately 70% for medically refractory epilepsy. The small sample size of the RCT cohort underscores the need to move beyond standard RCTs for epilepsy surgery. This historical seizure-freedom rate may serve as a useful benchmark to guide future study designs for new surgical treatments for refractory TLE.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Lee AT, Burke JF, Chunduru P, et al. A historical cohort of temporal lobe surgery for medically refractory epilepsy: a systematic review and meta-analysis to guide future nonrandomized controlled trial studies. J Neurosurg. 2019. PMID: 31252393. doi:10.3171/2019.4.JNS183235

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。